Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + celecoxib is a combination of two small molecule drugs, each with distinct but sometimes overlapping mechanisms of action. Aspirin (acetylsalicylic acid) is an irreversible inhibitor of cyclooxygenase-1 (COX-1), leading to reduced synthesis of thromboxane A2 and thus inhibiting platelet aggregation; it also inhibits cyclooxygenase-2 (COX-2) at higher doses, providing anti-inflammatory and analgesic effects. Celecoxib is a selective COX-2 inhibitor that reduces the formation of prostaglandins involved in pain and inflammation, with less effect on COX-1 than traditional NSAIDs. The combination has been studied for synergistic effects in cancer therapy—particularly non-small cell lung cancer—where it may enhance apoptosis, arrest the cell cycle, inhibit migration/invasion via MMP inhibition, and modulate ERK-MAPK signaling pathways[5]. However, celecoxib can attenuate the antiplatelet effect of low-dose aspirin by competing for COX-1 binding[1]. Both drugs are widely used individually for pain relief, inflammation reduction (arthritis), cardiovascular protection (aspirin), and certain cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + celecoxib.